Jump to Main Content

FDA Alerts

FDA Approves Hydroxyurea for Treatment of Pediatric Patients With Sickle Cell Anemia

The U.S. Food and Drug Administration granted regular approval to hydroxyurea (Siklos, Addmedica) to reduce the frequency of painful crises and the need for blood transfusions in pediatric patients from 2 years of age and older with sickle cell anemia with recurrent moderate to severe painful crises.